Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa trial of intravenous S95011 in primary Sjögren’s syndrome
2020-001526-59Phase 2Unknown
- Sponsor
- Servier
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing S95011 750 mg IV with Placebo IV (2 arms). Primary endpoint: Change in ESSDAI total score. Status: unknown.
02
Drugs
lusvertikimab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2020-001526-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001526-59.